10.390.58% ( +0.06 )
Delay Closed: Nov 13, 15:00:00Valuation
Current ValuationThe current P/E ratio is 16.81, within the reasonable range, cheaper than 45.12% of the time in the past 10 years, and the industry ranks 27/222, the industry Median 22.14.
16.81xP/E
¥10.39Stock price
¥0.62Earnings per share
16.81xP/E
Stock price¥10.39Earnings per share¥0.62
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 16.37x
- Typical range
- 14.26x–23.41x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 22.14x
015304560
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 22.14x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
000538SZYunnan Baiyao | 18.95x | 6.77% | ¥98.53B |
600196SHFOSUN PHARMA | 17.12x | 7.35% | ¥60.16B |
000999SZCR Sanjiu | 13.13x | 3.34% | ¥42.35B |
688578SHAllist | 12.64x | 31.69% | ¥36.73B |
600079SHHWHG | 12.56x | 28.07% | ¥32.43B |
000423SZDEEJ | 17.99x | 9.19% | ¥32.28B |
000513SZLIVZON GROUP | 18.06x | 17.70% | ¥28.12B |
600566SHJUMPCAN | 15.23x | -- | ¥27.66B |
002603SZYILING PHARMACEUTICAL | 18.59x | 14.94% | ¥25.70B |
600535SHTASLY | 17.07x | 17.08% | ¥20.89B |
000623SZJI LIN AO DONG | 6.63x | -- | ¥19.85B |
600380SHJoincare | 16.81x | 15.07% | ¥19.01B |
600062SHCR Double-Crane | 10.15x | 2.02% | ¥15.81B |
600267SHHISUN | 12.40x | 82.61% | ¥15.19B |
600750SHCRJZ | 17.10x | 3.92% | ¥14.38B |
600285SHLingrui Pharma | 15.60x | 9.20% | ¥12.91B |
605507SHGuobang Pharma | 19.42x | 12.03% | ¥12.08B |
300573SZXingqi Pharmaceutical | 14.86x | -- | ¥11.91B |
600993SHMYL | 18.04x | 14.44% | ¥10.73B |
002287SZCheezhengTTM | 16.77x | -- | ¥10.60B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
